Friday December 05 2008 | Biotechnology feed | All feeds
|
|
Friday December 05 2008 | Biotechnology feed | All feeds
|
|
|
Peakdale launches 5th Class A GPCR library and announces plans to develop other GPCR class libraries
Chapel-en-le-Frith, UK, August 8th, 2005
– Peakdale Molecular is launching the latest in its line of G-Protein Coupled
Receptor (GPCR) libraries, peakexplorer™ G5, at DDT, Boston, MA. This latest
expansion of the Company’s peakexplorer libraries is specifically designed,
synthesised and characterised for screening against aminergic GPCR targets.
Peakexplorer G5 is based on eight novel chemotypes,
covering over 1200 compounds, and brings the total offering of the
peakexplorer™ libraries to over 27 major chemotypes and more than 6000
purified and characterised drug-like compounds. The libraries, created using
Peakdale’s innovative chemistry expertise, include chemotypes derived from
novel Peakdale compounds and were designed using De Novo Pharmaceuticals’ in
silico pharmacophore modelling and virtual screening algorithms.
Dr Ray Fisher, Peakdale Molecular’s Commercial
Director, commented, “50% of all marketed drugs act on GPCRs, covering almost
every therapeutic application. Combining our medicinal chemists’ expertise and
our computational capabilities has provided compounds with excellent drug-like
properties and demonstrates our commitment to providing our customers with a
head start in their discovery activities. Building on the success of these we
are pleased to announce that we now plan to develop libraries focusing on
other classes of GPCRs.”
Peakdale is also extending its peakexplorer™ range
to include kinase libraries, starting with c-Abl Tyrosine Kinase. This will
further increase Peakdale’s offering of drug-like screening compounds to
produce high quality, patentable leads in the drive for new drugs.
About Peakdale Molecular Ltd: Peakdale Molecular was founded in 1992. Today, the Company’s customers include global pharmaceutical majors and an increasing number of biotechnology companies. Its team of chemists combines experience in pharmaceutical R&D and process development, fine chemicals, parallel synthesis and medicinal chemistry to deliver unique chemistry solutions to a range of drug discovery challenges. Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis and contract research chemistry. Further information about the Company can be obtained at www.peakdale.co.uk.
For more information please contact:
At the Company Kim Morrison, CEO +44 (0)1298 816700 kim.morrison@peakdale.co.uk On behalf of the Company Marc Egelhofer, Northbank Communications +44 (0)1260 296500 m.egelhofer@northbankcommunications.com
|
|
|
